Naturally Occurring Organic Sulfur Compounds Show Promise in Cancer Treatment

Strategic Insights -

Scientists in Luxembourg have made a significant breakthrough in cancer research by investigating the potential of naturally occurring organic sulfur compounds (OSCs) in treating leukemia. Their study, published in Apoptosis, has identified a compound, diallyltetrasulfide (Al2S4), which has shown promise in inducing apoptosis in cancer cells. The researchers found that Al2S4 induced an accumulation of cells in the early mitosis phase, followed by the activation of caspase-dependent apoptosis, and countered anti-apoptotic Bcl-2 family members.

Key Takeaways:

  • The study focused on naturally occurring organic sulfur compounds (OSCs), specifically linear allylsulfides from Allium species, which have been shown to have beneficial effects in cancer prevention and chemotherapy.
  • The researchers tested several OSCs and found that diallyltetrasulfide (Al2S4) induced apoptosis in U937 cells with an efficiency depending on the number of sulfides.
  • Al2S4 was found to induce an accumulation of cells in early mitosis (G2/M phase), followed by the activation of caspase-dependent apoptosis.
  • The compound counteracted different anti-apoptotic Bcl-2 family members, including Bcl-xL, phospho-Bad, and Bcl-2, and promoted activation of Bax and Bak.
  • Al2S4 also induced the release of cytochrome c into the cytoplasm and led to the identification of early apoptotic events, including Bcl-xL degradation, Bak activation, and release of cytochrome c.
  • The study suggests that naturally occurring OSCs, such as Al2S4, may have potential as a novel therapeutic approach for cancer treatment.

Statistics:

  • The study involved testing several OSCs, including diallyltetrasulfide (Al2S4), which showed promise in inducing apoptosis in U937 cells.
  • The compound Al2S4 induced apoptosis in U937 cells with an efficiency depending on the number of sulfides.
  • The study found that Al2S4 induced an accumulation of cells in early mitosis (G2/M phase) and activated caspase-dependent apoptosis.
  • The compound counteracted 3 different anti-apoptotic Bcl-2 family members, including Bcl-xL, phospho-Bad, and Bcl-2.

Sources:

  • Apoptosis, 2009;14(5):641-654
  • Leukemia
  • Blood Weekly via NewsRx.com
  • Hopital Kirchberg, Laboratory Biology Molecular & Cellulaire Cancer, Rue Edward Steichen 9, L-2540 Luxembourg, Luxembourg
  • Springer, Van Godewijckstraat 30, 3311 Gz Dordrecht, Netherlands